Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The product of MLYCD catalyzes the breakdown of malonyl-CoA to acetyl-CoA and carbon dioxide. Additionally we are shipping MLYCD Kits (4) and MLYCD Proteins (4) and many more products for this protein.
Showing 10 out of 12 products:
Human Polyclonal MLYCD Primary Antibody for WB - ABIN525162
Kulkarni, Salehzadeh, Fritz, Zierath, Krook, Osler: Mitochondrial regulators of fatty acid metabolism reflect metabolic dysfunction in type 2 diabetes mellitus. in Metabolism: clinical and experimental 2012
The MLYCD catalytic domain is structurally homologous to those of the GCN5-related N-acetyltransferase superfamily.
Structural asymmetry and disulfide bridges among subunits modulate the activity of human malonyl-CoA decarboxylase.
Our case emphasizes the need for ongoing cardiac disease screening in patients with MCD deficiency and the benefits and limitations of current dietary interventions.
This study of fatty acid oxidation and malonyl-CoA decarboxylase identifies a critical role for metabolism in both the normal pulmonary circulation (hypoxic pulmonary vasoconstriction) and pulmonary hypertension
Malonyl-CoA decarboxylase deficiency may result from MLYCD mutations that result in protein mistargeting.
The concentration of malonyl-CoA is diminished in muscle after physical training, most likely because of PGC-1alpha-mediated increases in MCD expression and activity.
analysis of nine novel MLYCD mutations in patients with malonyl-coenzyme A decarboxylase deficiency
MCD silencing suppresses lipid uptake and enhances glucose uptake in primary human myotubes.
Data suggest that increased expression of malonyl CoA decarboxylase, and the decreased expression of acetyl CoA carboxylase and 5'-AMP activated protein kinase (show PRKAA2 Antibodies) are important regulators of the maturation of fatty acid oxidation in the newborn human heart.
MCD(-/-) mice consistently exhibited cardiac dysfunction and severe metabolic perturbations while on a high-fat, low carbohydrate diet of maternal milk and these gradually resolved post-weaning.
Data indicate that a full-dosage of p53 (show TP53 Antibodies) and an intact ribosomal protein-murine double minute 2 protein (Mdm2 (show MDM2 Antibodies))-p53 (show TP53 Antibodies) pathway are required for the induction of malonyl coA decarboxylase (MCD), a critical regulator of fatty acid oxidation.
SIRT4 deacetylates and represses malonyl CoA decarboxylase, regulating malonyl coA levels.
In vivo and ex vivo cardiac function is similar in wild-type and mcd-deficient mice; however, deletion of MCD markedly increases glucose oxidation and improves functional recovery of the heart after ischemia.
Mcd deficiency is not detrimental to the heart in obesity in mice.
The product of this gene catalyzes the breakdown of malonyl-CoA to acetyl-CoA and carbon dioxide. Malonyl-CoA is an intermediate in fatty acid biosynthesis, and also inhibits the transport of fatty acyl CoAs into mitochondria. Consequently, the encoded protein acts to increase the rate of fatty acid oxidation. It is found in mitochondria, peroxisomes, and the cytoplasm. Mutations in this gene result in malonyl-CoA decarboyxlase deficiency.
MaLonyl CoA Decarboxylase family member (mlcd-1)
, malonyl coenzyme A decarboxylase
, malonyl-CoA decarboxylase, mitochondrial